Bank of New York Mellon’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-7,692
| Closed | -$347K | – | 4134 |
|
|
2024
Q1 | $347K | Sell |
7,692
-215
| -3% | -$9.7K | ﹤0.01% | 3707 |
|
|
2023
Q4 | $373K | Sell |
7,907
-94
| -1% | -$4.44K | ﹤0.01% | 3703 |
|
|
2023
Q3 | $324K | Buy |
8,001
+931
| +13% | +$37.7K | ﹤0.01% | 3768 |
|
|
2023
Q2 | $753K | Buy |
7,070
+2,249
| +47% | +$240K | ﹤0.01% | 3366 |
|
|
2023
Q1 | $1.44M | Buy |
4,821
+324
| +7% | +$96.7K | ﹤0.01% | 2972 |
|
|
2022
Q4 | $1.55M | Buy |
4,497
+421
| +10% | +$145K | ﹤0.01% | 2984 |
|
|
2022
Q3 | $771K | Buy |
4,076
+275
| +7% | +$52K | ﹤0.01% | 3329 |
|
|
2022
Q2 | $802K | Buy |
3,801
+152
| +4% | +$32.1K | ﹤0.01% | 3316 |
|
|
2022
Q1 | $1.22M | Buy |
3,649
+102
| +3% | +$34.1K | ﹤0.01% | 3192 |
|
|
2021
Q4 | $1.15M | Buy |
3,547
+161
| +5% | +$52.4K | ﹤0.01% | 3299 |
|
|
2021
Q3 | $1.65M | Buy |
3,386
+282
| +9% | +$137K | ﹤0.01% | 3105 |
|
|
2021
Q2 | $1.44M | Sell |
3,104
-676
| -18% | -$314K | ﹤0.01% | 3201 |
|
|
2021
Q1 | $2.61M | Sell |
3,780
-84
| -2% | -$58K | ﹤0.01% | 2768 |
|
|
2020
Q4 | $2.86M | Buy |
3,864
+389
| +11% | +$288K | ﹤0.01% | 2636 |
|
|
2020
Q3 | $2.41M | Buy |
3,475
+197
| +6% | +$137K | ﹤0.01% | 2557 |
|
|
2020
Q2 | $2.78M | Buy |
3,278
+162
| +5% | +$137K | ﹤0.01% | 2492 |
|
|
2020
Q1 | $1.12M | Buy |
3,116
+1,902
| +157% | +$681K | ﹤0.01% | 2894 |
|
|
2019
Q4 | $284K | Hold |
1,214
| – | – | ﹤0.01% | 3819 |
|
|
2019
Q3 | $137K | Buy |
1,214
+84
| +7% | +$9.48K | ﹤0.01% | 3967 |
|
|
2019
Q2 | $198K | Buy |
+1,130
| New | +$198K | ﹤0.01% | 3921 |
|